Yichang Humanwell Pharmaceutical secures Canadian market authorization for Bupropion Hydrochloride Extended-Release Tablets (XL)

Yichang Humanwell Pharmaceutical's  Bupropion Hydrochloride Extended-Release Tablets (XL) have recently received a market authorization issued by Health Canada. The approved indications are for the relief of symptoms of major depressive disorder and the prevention of seasonal major depressive episodes in autumn and winter, with available strengths of 150mg and 300mg.

Bupropion hydrochloride is an aminoketone-class antidepressant. As a norepinephrine and dopamine reuptake inhibitor (NDRI), it exerts its antidepressant effect by inhibiting the reuptake of norepinephrine and dopamine. While effectively alleviating depressive symptoms, the drug is less likely to cause other common side effects such as weight gain, sexual dysfunction, or drowsiness, thereby demonstrating a differentiated safety profile. Its extended-release formulation (XL) provides stable controlled drug release, further enhancing patient medication adherence and tolerability.

The approval of Bupropion Hydrochloride Extended-Release Tablets (XL) marks the first product for which Yichang Humanwell Pharmaceutical independently held the application and obtained the market authorization in Canada. This achievement provides crucial product support for the company's entry into the North American market and represents another significant breakthrough in advancing its internationalization strategy.

Source: Yichang Humanwell Pharmaceutical